OptimizeRx (OPRX) Common Equity (2010 - 2026)

OptimizeRx (OPRX) has 17 years of Common Equity data on file, last reported at $129.6 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 11.47% year-over-year to $129.6 million; the trailing twelve-month figure through Mar 2026 stood at $129.6 million (up 11.47% YoY), and the FY2025 full-year result was $128.3 million, up 9.65% from the prior year.
• Common Equity grew to $129.6 million in Q1 2026, from $128.3 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $140.8 million in Q2 2022 to a low of $114.5 million in Q3 2024.
• A 5-year average of $123.6 million and a median of $122.5 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity rose 12.95% in 2022 and slipped 17.76% in 2023, its largest moves.
• Tracing OPRX's Common Equity over 5 years: stood at $126.1 million in 2022, then rose by 0.35% to $126.6 million in 2023, then dropped by 7.55% to $117.0 million in 2024, then climbed by 9.65% to $128.3 million in 2025, then advanced by 1.03% to $129.6 million in 2026.
• Business Quant data shows OPRX's Common Equity at $129.6 million in Q1 2026, $128.3 million in Q4 2025, and $122.3 million in Q3 2025.